The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

GLP-1 receptor agonists, a diabetic medication may help in reducing alcohol consumption and alcohol-related health problems.

Sadiya Khan At the policy level, Khan et al highlighted issues around high out-of-pocket costs, restrictions placed on the ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

[5] Dulaglutide: A type of glucagon-like peptide-1 (GLP-1) receptor agonist approved by the U.S. Food and Drug Administration ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes ... Perceived high costs, inconsistent insurance ...

GLP-1 receptor agonists and SGLT2 inhibitors ... are approved by the U.S. Food & Drug Administration for weight loss and to ...